GLP 1 peritoneal dialysis records tie longer drug use to modest weight loss

A large records study presented at Kidney Week 2026 in Denver adds early GLP 1 peritoneal dialysis data to a field where trials rarely look. Among adults with type 2 diabetes who started this home form of dialysis, those with more cumulative time on GLP 1 receptor agonists lost more weight and spent less modelled time in hospital. The analysis came from DaVita Clinical Research and was shown as a poster. HCPLive interviewed one of its authors, Steven Brunelli, and he stressed that it is not a trial.

Why dialysis patients are a gap in the evidence

Peritoneal dialysis uses the lining of the abdomen as a filter. A sugar based fluid is run into the belly, left to draw out waste and water, then drained, usually at home. For people with type 2 diabetes that fluid adds a steady glucose load, on top of high cardiovascular risk and the gradual loss of residual kidney function, the small amount of filtering the kidneys still manage. GLP 1 drugs have strong trial evidence in kidney disease. In the FLOW trial, semaglutide lowered the risk of cardiovascular death in people with type 2 diabetes and chronic kidney disease. People on dialysis, however, were not the focus of such trials, so doctors have had little to go on.

Brunelli put the problem plainly in his interview. "In general, dialysis patients, and in particular peritoneal dialysis patients, don't make it into the landmark clinical trials," he told HCPLive. That leaves clinicians to guess whether results from broader groups carry over to people whose biology and daily routine differ so much. Weight is also a harder outcome to read in this group than in the general population. Many people on dialysis are frail, and the scale alone says nothing about whether lost weight came from fat, muscle or fluid. A drug that reduces appetite therefore needs to be judged on more than the number it moves. The study tried to address part of that by tracking hospital use, fluid removal and urine output alongside weight.

What the GLP 1 peritoneal dialysis cohort measured

The team used a retrospective cohort of 5,897 adults with type 2 diabetes who began peritoneal dialysis between April 2021 and September 2024 in DaVita clinics. Of these, 516 people, or 8.7 percent, started a GLP 1 receptor agonist at some point. Follow up began 90 days after dialysis started. Each stretch of patient time was classed as drug use or control according to prescription records, so a person could move between the two groups. The authors then used marginal structural models with stabilised inverse probability weights, a method meant to balance treated and untreated time when treatment choices shift over months. The main outcome was relative change in body weight. Hospitalisation, ultrafiltration and urine output were secondary, while blood sugar and death were exploratory.

More cumulative exposure to the drugs went with steadily greater weight loss, about 1.19 percentage points overall and 0.73 points for each extra quarter of use.

More cumulative exposure to the drugs went with steadily greater weight loss, about 1.19 percentage points overall and 0.73 points for each extra quarter of use. When the analysis was limited to new users the overall figure grew to 1.69 points. The modelled hospitalisation rate fell with exposure, with a rate ratio of 0.935 for each quarter, which works out to a modelled rate about 6.5 percent lower for each quarter of use. Ultrafiltration indexed to body surface area and urine output showed no significant link, which is mildly reassuring for residual kidney function but not proof that the drugs protect it. Blood sugar results broke a key assumption of the method and were reported only descriptively, and the mortality estimate, a hazard ratio of 0.706, was too imprecise to read.

The numbers and where they came from

Put side by side, the results show a pattern of small, consistent associations rather than a dramatic effect. A difference of about one percentage point in relative weight change is modest when set against the much larger losses reported in obesity trials of the same drug class, although people on dialysis start from a very different place. The hospital finding is the more interesting one for patients, because admissions are common and disruptive in this group. Yet it is also the result most exposed to bias, since healthier patients may be both more likely to receive a new drug and less likely to be admitted. The table below gathers the main GLP 1 peritoneal dialysis figures as they were reported by HCPLive.

All of these figures come from a conference abstract and its coverage, not from a peer reviewed paper with full methods and supplementary tables. The poster, numbered FR-PO1115, lists Luo, Sibbel, Weinhandl and colleagues as authors, and Brunelli is vice president and medical director for health analytics at DaVita Clinical Research. DaVita runs the dialysis clinics whose records were used, and Brunelli reported ties to the company. That does not make the numbers wrong, but readers should know who collected and analysed them. The full HCPLive account, including the interview, is available from the HCPLive report, which cites the abstract and the FLOW trial paper.

What observational records cannot settle

The central weakness is the one Brunelli named himself. "It's still an observational study. It's not the same as a clinical trial," he said. Doctors chose who received the drugs, and the reasons behind those choices, such as better appetite, fewer stomach problems or more contact with the clinic, may also shape weight and hospital use. Weighting methods adjust for measured factors and can still miss unmeasured ones. The hospital result was a modelled burden, not a count of specific admissions prevented, and the study did not report body composition, so it cannot say whether the weight lost was fat or muscle. Readers who followed earlier records studies of GLP 1 drugs will recognise both the value and the limits of this kind of evidence.

The practical reading offered by the author was cautious. Brunelli told HCPLive that for suitable patients clinicians "shouldn't deny the patients the GLP-1 specifically because they're on peritoneal dialysis." That is a statement about not excluding people, not a claim that the drugs improve survival on dialysis, which the data cannot support. The investigators say prospective studies are needed, and Brunelli hopes the work helps justify a dedicated trial in this group. Such a trial would also need to track what happens if the drug is stopped, since weight returns quickly after withdrawal in other populations. Until then, this cohort is a signal that the drugs behave in dialysis much as elsewhere.

Conclusion

The GLP 1 peritoneal dialysis cohort suggests that weight loss seen with these drugs in the wider population may also occur in people with type 2 diabetes on home dialysis, along with fewer modelled hospital stays. The effect on weight was modest and the evidence is a meeting poster built on one provider's records. It cannot show cause, survival benefit or the quality of the weight lost, which is what a dedicated trial would need to answer.

Source Luo J, Sibbel S, Weinhandl ED and colleagues. GLP-1 receptor agonist exposure and longitudinal outcomes in patients with type 2 diabetes initiating peritoneal dialysis. ASN Kidney Week 2026, poster FR-PO1115, as reported by HCPLive

Amino Weekly reports research. It is not medical advice and never gives doses.